Skip Main Navigational Links to Main Body
About UsWhat's NewStructureServicesProductsUseful Links
Skip About Us to Structure
About Us Home
Mission Statement
Our Objective
Corporate Profile
Management Team
Skip Structure to Services
Press Release
Skip Services to Products
Biotechnology Incubation Centre
Biologics Unit
GMP Consultation Services
Traditional Chinese Medicine
Skip Pipeline to Newsroom
Biotechnology Incubation Centre
Biologics Unit
GMP Consultation Services
Traditional Chinese Medicine
Skip Newsroom to Investors
LifeArtTM Products
Skip Investors to Careers
Related C.U.H.K Unit
Regulatory Authorities
Local Information Sources
Biotech related information in HK
Skip Careers to Main Body
Enquiries Home
Biotechnology Unit
Incubation Centre
Traditional Chinese Medicine

Site Index


Board of Directors
Management Board
The Directors
Unit Heads
Professor Dominic LAM was born in Swatow, China and received his early education in Hong Kong. He received his BSc in mathematics from Lakehead University in 1967, his MSc in theoretical physics from the University of British Columbia in 1968 and his Ph.D. in medical biophysics from the University of Toronto in 1970. Professor Lam was a faculty member at the Harvard Medical School and the Baylor College of Medicine in the 80’s and he was also the Chairman of Houston Biotechnology Incorporation at the same period.
Professor LAM has published more than 180 scientific papers and abstracts. His research interest and publications are mainly in the areas of molecular mechanisms underlying neuronal communication in general, and the processing of
visual information in particular. The vertebrate retina has been his model system for such studies. His research focus was on the use of transmitters and neuropeptides as physiological probes to study the organization and development of the retina. He was appointed the first Managing Director of HKIB in 1988.
Professor Kin-ping WONG received his Bachelor degree in Chemistry from the University of California, Berkeley in 1964 and his Ph.D. in Physical Chemistry and Biochemistry from Prudue University in 1968. After being a postdoctoral fellow in Duke University Medical Center, he traveled to Germany and Sweden and began his scientific career as a Visiting Scientist and Senior Fellow there. He held important positions in different professional associations and major U.S. universities. First as a Research Associate at Duke University, then as Assistant and Associate Professor at University of South Florida, and subsequently Associate, Full Professor, and Dean of Graduate Studies at University of Kansas. Before his appointment as Director of HKIB in 1993, he was the Dean and
Professor at the California State University, Fresno and Adjunct Professor of Medicine and Biochemistry and Biophysics at the University of California San Francisco.
Dr. Wong carried out extensive research in Biochemistry and Molecular Biology. His fields of studies include the biochemistry of proteins, the molecular basis of cancer and protein candidates for cancer therapy, the folding and stability of RNA and more recently the molecular biology of angiogenesis and its inhibitors. Professor Wong has published more than 80 conference papers and research articles as well as 2 major science textbooks. He has secured a total of 12 U.S. Patents on his work in angiogenesis inhibitors.
Dr. Albert CHANG received his BSc degree from the National Taiwan University in 1958 and the MSc degree from the University of California, Berkeley in 1962. After he obtained his Ph.D. in Biochemistry at the University of Illinois, he continued to work as a post-doctoral fellow in the Virus Laboratory of the same university up to 1967. From 1967 to 1993, Dr. Chang developed his career in the pharmaceutical industry in the Upjohn Company where he first held the position of a Research Scientist and later became a senior administrator holding the position of Research Head, AssociateDirector, Strategic Planning and International Liaison Director of Pharmaceutical Research and finally the International Liaison Director in 1990.
While at the Upjohn Company, Dr. Chang led a number of projects on the discovery and development of new therapy for diabetes mellitus and on defining the marketing strategy of anti-diabetic products. The development of ciglitazone, a breakthrough oral hypoglycemic drug candidate for non-insulin-dependent diabetes mellitus (NIDDM) patients, in collaboration with Takeda Chemical Industry of Japan, was a milestone of Upjohn as well as Dr. Chang’s statuein pharmaceutical research.
Apart from his professional positions in the Upjohn Company, Dr. Chang was an active scientistand scholar holding a number of ancillary positions in the United States, Taiwan, and China. He has published more than 100 scientific papers in peer-reviewed journals, book chapters, and conference papers. And he has also been invited to lecture in universities and biotechnology conferences in different countries. He himself also organized a number of workshops and symposia related to diabetes research and biotechnology since 1974.
Dr. Albert Chang took up his Directorship of our institute from 1994 to 1999 after he has been the Managing Director of Pharmaceutical R&D Laboratories, Development Centre for Biotechnology, Taiwan for 3 years. Under his leadership our institute has grown tremendously in the past ten years and now it is recognized as a key organization in Chinese medicine development and biotechnology in Hong Kong.
Dr. Shawn LEUNG received his BSc in Biochemistry and M. Phil.degrees from the Chinese University of Hong Kong in 1984 and 1986, respectively. He finished his Ph.D. in Molecular Biology from the University of Oxford, England in 1989, and his research was focused on studying the transcription and translation of the human q-globulin gene. Subsequently, he joined the Yale University as a postdoctoral fellow and worked in the field of immunobiology until he took the position as Associate Director, Division of Molecular Biology Immunomedics, Inc., New Jersey. Later he became the Director and the Executive Director in Biology Research of Immunomedics. In 2000, Dr. Leung took up the position as the Managing Director of the Hong Kong Institute of Biotechnology where he stayed until the end of 2002.
Dr. Leung’s research interest was in cancer research and the immune system. He has published a large number of papers in peer-reviewed journals such as Nature, Clinical Cancer Research, Hybridoma, Cancer Research, Molecular Immunology, Journal of Immunology, International Journal of Cancer, and Immunopharmacology. He has won a number of research grants from the National Institutes of Health and the National Cancer Institute in the study of immunology and cancer. His work on immunoconjugates and antibody for clinical therapy has resulted in 13 US Patents. Dr. Leung has contributed significantly to the field of immunotherapy using monoclonal antibodies.
Professor Walter HO is presently the Honorary Professor, School of Biomedical Sciences of The Chinese University of Hong Kong (CUHK) , Medical Faculty; Adjunct Professor, School of Life Sciences, Science Faculty and Co-Covener, Drug Development Section, Insitute of Chinese Medicine. He obtained his undergraduate degree in Biochemistry and Economics and Ph.D. degree in Biophysics from the University of California, Berkeley.
Professor HO actively participates in the promotion of biotechnology in Hong Kong. From 1995 to 1999, he was a member of the Biotechnology Committee under the Hong Kong Government Industry Department. He is also a founding and council member of the Hong Kong Biotechnology Association. In addition, he has organized a number of conferences and
workshops in various biotechnology topics. Professor HO is currently honorary professor of the Guangzhou Medical University and Zhejiang Academy of Agricultural Sciences in China and he has also acted as consultants to a number of biotechnology companies in Hong Kong.
Prof. Cheng Hon-ki Christopher, is presently professor in the School of Biomedical Sciences of The Chinese University of Hong Kong (CUHK) and is the founding chief of the Reproduction, Development and Endocrinology Theme of the school. Prof. Cheng was the Associate Director of the Institute from 2006 to 2010. Having previously worked in Genentech Inc. in the San Francisco Bay Area, Professor Cheng has actively participated in the business development and translational activities of the institute in the past few years. A CUHK graduate, Professor Cheng obtained his B.Sc. degree (First Class Honours) in biochemistry in 1976. He subsequently pursued graduate studies at University College London as a Shell Scholar, receiving his Ph.D. in biochemistry in 1980. Professor Cheng then moved to the University of California at San Francisco to work under the mentorship of the late renowned biochemist, Prof. Choh Hao Li. In 1981, he returned to Hong Kong to join his alma mater.
Professor Cheng’s major research interests are molecular endocrinology and the development of therapeutic agents from natural and synthetic compounds. In collaboration with scientists from mainland China, Professor Cheng received the prestigious State Natural Science Award (Second Class) in 2009 for the project ‘Composition analysis of certain medicinally important plants’, which has contributed significantly to the development of botanical resource and natural product chemistry in China. He has served as visiting professor in a number of universities on the mainland, including Zhejiang University, Sun Yat-sen University and Southwest University.
The Hong Kong Institute of Biotechnology Limited.
2 Biotechnology Avenue, 12 Miles, Tai Po Road, Shatin, N.T., Hong Kong. Tel: (852) 26035111, Fax: (852) 26035012
Copyright 2005 © The Hong Kong Institute of Biotechnology Limited. All rights reserved.